Funder
Foundation for the National Institutes of Health
the Gloria Borges Wunderglo Project
Dhont Family Foundation
Daniel Butler Research Fundation
Call to Cure Research Fundation
Japan Society for the Promotion of Science
Takashi Tsuruo Memorial Fundation
Werner and Hedy Berger-Janser Foundation
Publisher
Public Library of Science (PLoS)
Reference49 articles.
1. Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity;SM Wilhelm;Int J cancer,2011
2. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial;A Grothey;Lancet,2013
3. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial;J Li;Lancet Oncol,2015
4. Network NCC. National Comprehensive Cancer Network (NCCN). Guidel Version 1 2016 Colon Cancer. 2016. Available: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001308/
5. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;E Van Cutsem;Ann Oncol,2016
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献